Cancer Chemoprotection by Oltipraz: Experimental and Clinical Considerations

Preventive Medicine

Volumn 22, Issue 5, 1993, Pages 783-795

  Helzlsouer, Kathy J ^a,b   Kensler, Thomas W ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; AZOXYMETHANE; BENZO[A]PYRENE; BETA CAROTENE; CYTOCHROME P450; DIETHYLNITROSAMINE; DIMETHYLBENZ[A]ANTHRACENE; EFLORNITHINE; FENRETINIDE; GLUTATHIONE; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; OLTIPRAZ; URAMUSTINE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME INDUCTION; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL;

ANIMAL; ANTICARCINOGENIC AGENTS; CLINICAL TRIALS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMAN; MALE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PYRAZINES; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027377850     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1006/pmed.1993.1072     Document Type: Article

References (63)

1. Lozac’h N, Vialle J. The chemistry of the 1, 2-dithiole ring. In: Kharasch N, Meyers CY, Eds. The Chemistry of Organic Sulfur Compounds, Vol. 2. Oxford: Pergamon, 1966: 257-285.
2. Leroy J-P, Barreau M, Cotrel C, Jeanmart C, Messer M, Benazet F, Laboratory studies of 35 972 R.P. A new schistosomicidal compound. In: Siegenthaler W, Luthy R, Eds. Current Chemotherapy, Proceedings of the 10th International Congress of Chemotherapy. Washington, DC: American Society for Microbiology, 1978: 148-150.
3. Bueding E, Dolan P, Leroy J-P. The antischistosomal activity of oltipraz. Res Commun Chem Pathol Pharmacol 1982; 37:293-303.
4. Gentilini M, Duflo B, Richard-Lenoble D, Brucker G, Danis M, Niel G, Meunier Y. Assessment of 35972 RP (Oltipraz) a new antischistosomal drug against Schistosoma haematobium, Schistosoma monsoni, and Schistosoma intercalatum. Acta Trap 1980; 37:271-274.
5. Kern P, Burchard GD, Dietrich M. Comparative study of oltipraz versus praziquantel for treat ment of schistosomiasis with intestinal manifestation in the Gabon (Schistosoma intercalatum and 5. haematobium). Tropenmed Parasitol 1984; 35:95-99.
6. Kardaman MW, Fenwick A, Igail ABE, Tayeb ME, Bennett JL, Daffalla AA. Field trials with oltipraz against Schistosoma mansoni in the Gezira Irrigated Area, Sudan. J Trap Med Hyg 1985; 88:95-100.
7. Hausler R, Ritschard J. Clinical study with a sialagogue drug (Sulfarlem S 25 = TTPT) in the treatment of xerostomia. Rev Suisse Praxis Med 1979; 68:1063-1068.
8. Moreau N, Martens T, Fleury M-B, Leroy J-P. Metabolism of oltipraz and glutathione reductase inhibition. Biochem Pharmacol 1990; 40:1299-1305.
9. Mkoji GM, Smith JM, Pritchard RK. Effect of oltipraz on the susceptibility of adult Schistosoma mansoni to killing by mouse peritoneal exudate cells. Parisilol Res 1990; 76:435-439.
10. Ansher SS, Dolan P, Bueding E. Biochemical effects of dithiolethiones. Food Chem Toxicol 1986; 24:405-415.
11. Benson AM, Batzinger RP, Ou S-YL, Bueding E, Cha Y-N, Talalay P. Elevation of hepatic glutathione 5-transferase activities and protection against mutagenic metabolites of benzo[a]py-rene by dietary antioxidants. Cancer Res 1978; 38:4486-4495.
12. Benson AM, Cha Y-N, Bueding E, Heine HS, Talalay P. Elevation of extrahepatic gluthathione 5-transferase and epoxide hydratase activities by 2(3)-tert-butyl-4-hydroxyanisole. Cancer Res 1979; 39:2971-2977.
13. Ansher SS, Dolan P, Bueding E. Chemoprotective effects of two dithiolethiones and of butylhy-droxyanisole against carbon tetrachloride and acetaminophen toxicity. Hepatology 1983; 3:932-935.
14. Davies MH, Schamber GJ, Schnell RC. Role of glutathione in oltipraz-induced protection in acetaminophen or allyl alcohol hepatotoxicity in the male hamster. The Toxicologist 1987; 7:219.
15. Davies MH, Schamber GJ, Schnell RC. Oltipraz-induced amelioration of acetaminophen hepato toxicity in hamsters. Toxicol Appl Pharmacol 1991; 109:17-28.
16. Liu L-Y, Roebuck BD, Yager JD, Groopman JD, Kensler TW. Protection by 5-(2-pyrazinyl)-4-methyl-l, 2-dithiol-3-thione (oltipraz) against the hepatotoxicity of aflatoxin B, in the rat. Toxicol Appl Pharmacol 1988; 93:442-451.
17. Wattenberg LW, Bueding E. Inhibitory effects of 5-(2-pyrazinyl)-4-methyl-l, 2-dithiol-3-thione (oltipraz) on carcinogenesis induced by benzo[a]pyrene, diethylnitrosamine and uracil mustard Carcinogenesis 1986; 7:1379-1381.
18. Rao CV, Tokomo K, Kelloff G, Reddy BS. Inhibition by dietary oltipraz of experimental intestinal carcinogenesis induced by azoxymethane in male F344 rats. Carcinogenesis 1991; 12:1051-1055.
19. Roebuck BD, Liu Y-L, Rogers AR, Groopman JD, Kensler TW. Protection against aflatoxin B,-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-l, 2-dithiole-3-thione (oltipraz): Predictive role for short-term molecular dosimetry. Cancer Res 1991; 51:5501-5506.
20. Kensler TW, Egner PA, Dolan PM, Groopman JD, Roebuck BD. Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-l, 2-dithiol-3-thione (oltipraz) and related 1, 2-dithiole-3-thione and l, 2-dithiol-3-ones. Cancer Res 1987; 47:4271-4277.
21. Pepin P, Bouchard L, Nicole P, Castonguay A. Effects of sulindac and oltipraz on the tumorige nicity of 4-(methylnitrosamino)l-(3-pyridyl)-l-butanone in A/J mouse lung. Carcinogenesis 1992; 13:341-348.
22. Thomas CF, Detrisac CJ, Moon RC, Kelloff GJ. Combination chemoprevention of experimental bladder cancer. Proc Am Assoc Cancer Res 1992; 33:169.
23. Moon RC, Rao KVN, Detrisac CJ, Kelloff GJ. Retinoid chemoprevention of lung cancer. In: Wattenberg LW, Boone CW, Kelloff GJ, Lipkin M, Eds. Cancer Chemoprevention, Boca Raton: CRC Press, 1992. In press.
24. Essigmann JM, Croy RG, Nadzan AM, Busby WF Jr, Reinhold VN, Biichi G, Wogan GN. Structural identification of the major DNA adduct formed by aflatoxin, in vitro. Proc Natl Acad Sci USA 1977; 74:1870-1874.
25. Degan GH, Neumann HG. The major metabolite of aflatoxin Bj in the rat is a glutathione conjugate. Chem-Biol Interact 1978; 22:239-255.
26. Kensler TW, Egner PA, Trush MA, Bueding E, Groopman JD. Modification of aflatoxin B, binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiolethione. Carcinogenesis 1985; 6:759-763.
27. Kensler TW, Davidson NE, Egner PA, Guyton KZ, Groopman JD, Curphey TJ, Liu Y-L, Roebuck BD. Chemoprotection against aflatoxin-induced hepatocarcinogenesis by dithiolethiones. In: Bray GA, Ryan DH, Eds. Mycotoxins, Cancer and Health, Baton Rouge: LSU Press, 1991: 359-371.
28. Coles B, Meyer DJ, Ketterer B, Stanton CA, Garner RC. Studies on the detoxication of microso-mally-activated aflatoxin B, by glutathione and glutathione transferases in vitro. Carcinogenesis 1985; 6:693-697.
29. Guengerich FP, Raney KD, Kim D-H, Shimada T, Meyer DJ, Ketterer B, Harris TM. Oxidation and conjugation of aflatoxins by humans and experimental animals. In: D’Amato R, Slaga TJ, Farland W, Henry C, Eds. Relevance of Animal Studies to the Evaluation of Human Cancer Risk. New York: Wiley-Liss, 1992: 157-165.
30. Davidson NE, Egner PA, Kensler TW. Transcriptional control of glutathione S-transferase gene expression by the chemoprotective agent 5-(2-pyrazinyl)-4-methyl-l, 2-dithiole-3-thione (olti-praz) in rat liver. Cancer Res 1990; 50:2251-2255.
31. Rushmore TH, King RG, Paulson KE, Pickett CB. Regulation of glutathione S-transferase Ya subunit gene expression: Identification of a unique xenobiotic-responsive element controlling inducible expression by planar aromatic compounds. Proc Natl Acad Sei USA 1990; 87:3826-3830.
32. Putt DA, Kensler TW, Hollenberg PF. Effects of three chemoprotective antioxidants, ethoxyquin, oltipraz and l, 2-dithiole-3-thione, on cytochrome P-450 levels and aflatoxin B, metabolism. FASEBJ 1991; 5:A1517.
33. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991; 4:391—407.
34. 7-guanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. Cancer Res 1986; 46:3924-3931.
35. Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science 1990; 249:1007-1011.
36. Byar DP. The design of cancer prevention trials. Recent Results Cancer Res 1988; 111:24—48.
37. Benson AB III, Mobarhan S, Ratain M, Sheehan T, Berezin F, Giovanazzi-Bannon S, Ford C, Rademaker A. Phase I study of 4-methyl-5-(2-pyrazinyl)-l, 2-dithiole-3-thiol [oltipraz: RP 35972] in male patients with previously resected colon polyps and first degree relatives of breast cancer patients. Proc Am Assoc Clin Oncol 1992; 11:145.
38. Pieron R, Lesobre Y, Mafart D, Meyniel F, Lancastre F, Renard A, Simon J, Grégoire J, Bassett P. L’oltipraz en traitment d’un jour dans la bilharziose à Schistosoma haematobium (données pharmacocinétiques, effets thérapeutiques). Revue de Médicine interne 1981; 2:231-237.
39. Berezin F, Ratain MJ, Benson AB III. Pharmacokinetic study of 4-methyl-5(2-pyrazinyl)-l, 1-dithiole-3-thione (oltipraz) in normal volunteers. Proc Am Assoc Cancer Res 1992; 33:208.
40. Rao CV, Nayini J, Reddy BS. Effect of oltipraz [5-(2-pyrazinyl)-methyl-l, 2-dithiole-3-thione] on azoxymethane-induced biochemical changes related to early colon carcinogenesis in male F344 rats. Proc Soc Exp Biol Med 1991; 197:77-84.
41. De Long MJ, Dolan P, Santamaria AB, Bueding E. 1, 2-Dithiol-3-thione analogs: effects on NAD-(P)H:quinone reductase and glutathione levels in murine hepatoma cells. Carcinogenesis 1986; 7:977-980.
42. Gordon GB, Prochaska HJ, Yang LY-S. Induction of NADP(P)H:quinone reductase in human peripheral blood lymphocytes. Carcinogenesis 1991; 12:2392-2396.
43. l4C-oltipraz in animals. Arzneim—Forsch 1985; 35:1431-1436.
44. Bieder A, Decouvelaere B, Gaillard C, Depaire H, Heusse D, Ledoux C, Lemar M, Le Roy J-P, Raynaud L, Snozzi C, Grégoire J. Comparison of the metabolism of oltipraz in the mouse, rat and monkey and in man. Arzneim—Forsch 1983; 33:1289-1297.
45. Moreau N, Martens T, Fleury M-B, Leroy J-P. Metabolism of oltipraz and glutathione-reductase inhibition. Biochem Pharmacol 1990; 40:1299-1305.
46. Ross RK, Yuan J-M, Yu MC, Wogan GN, Qian G-S, Tu J-T, Groopman JD, Gao Y-T, Henderson BE. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339:943-946.
47. Motykiewicz G, Michalska J, Pendzich J, Perera FP, Chorazy M. A cytogenetic study in a population exposed to airborne pollutants. Proc Am Assoc Cancer Res 1992; 33:292.
48. Perera FP, Santella R, Grzybowska E, Motykiewicz G, Dickey C, Young TL, Blaner B, Chorazy M, Hemminki K. DNA adducts and related biomarkers in a population exposed to airborne carcinogens. Proc Am Assoc Cancer Res 1992; 33:292.
49. United States Department of Health, Education, and Welfare, National Institute for Occupational Safety and Health. Occupational Diseases: A Guide to Their Recognition. 1977: 471-472.
50. Sankila R, Karjalainen S, Laara E, Pukkala E, Teppo L. Cancer risk among health care personnel in Finland, 1971-1980. Scan J Work Environ Health 1990; 16:252-257.
51. Skov T, Lynge E, Marrup B, Olsen J, Rorth M, Winthereik H. Risks for physicians handling antineoplastic drugs. Lancet 1990; 2:1446.
52. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin’s disease. N Engl J Med 1988; 318:76-81.
53. Evans HJ. Chromosome aberrations induced by ionizing radiations. Int Rev Cytol 1962; 13:221-321.
54. Stucker I, Hirsch A, Doloy T, Bastie-Sigeac I, Hemon D. Urine mutagenicity, chromosomal abnormalities and sister chromatid exchanges in lymphocytes of nurses handling cytostatic drugs. Int Arch Occup Environ Health 1986; 57:195-205.
55. Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ, Hong WK. Biomarkers as inter mediate end points in chemoprevention trials. J Natl Cancer Inst 1990; 82:555-560.
56. Bennett RA, Essigmann JM, Wogan GN. Excretion of an aflatoxin-guanine adduct in urine of aflatoxin B,-treated rats. Cancer Res 1981; 41:650-654.
57. 7-guanine and other aflatoxin metabolites by multiple monoclonal antibody affinity chromatography and immunoaffinity/high performance liquid chromatography. Cancer Res 1992; 52:267-274.
58. Groopman JD, Zhu J, Donahue PR, Pikul A, Zhang L, Chen J, Wogan GN. Molecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi Autonomous Region, People’s Republic of China. Cancer Res 1992; 52:45-52.
59. 7-guanine and serum aflatoxin-albumin adducts predicts chemoprotection by 1, 2-dithiole-3-thione in rats. Carcinogenesis 1992; 13:101-106.
60. Tangrea JA, Adrianza ME, Helsel WE. Patients' perceptions on participation in a cancer chemo prevention trial. Cancer Epi Biomarkers Prev 1992; 1:325-330.
61. Boone CW, Kelloff GJ, Malone WE. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: A review. Cancer Res 1990; 50:2-9.
62. Steele VE, Sigman CC, Boone CW, Kelloff GJ. Efficacy of cancer chemopreventive agents in different animal organ systems. Proc Am Assoc Cancer Res 1992; 33:159.
63. Helmes CT, Becker RA, Seidenberg JM, Schindler JE, Kelloff G. Chemoprevention of mouse skin tumorigenesis by dietary oltipraz. Proc Am Assoc Cancer Res 1989; 30:177.